Alpha Quant Advisors’s Myriad Genetics MYGN Stock Holding History

Alpha Quant Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$8K	Hold	244	–	–	0.01%	266
2018 Q4	$7K	Buy	+244	New	+$8.78K	0.01%	284

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Alpha Quant Advisors's MYGN Position: Q1 2019 in Review

Alpha Quant Advisors held its Myriad Genetics (MYGN) position steady in Q1 2019 at 244 shares worth $8K. The position accounts for 0.01% of the portfolio, ranked #266.

Alpha Quant Advisors first reported a position in MYGN in Q4 2018 and has held it in 2 quarters since. 262 funds tracked by Wall St. Rank hold MYGN as of Q1 2019.

Alpha Quant Advisors held 244 shares of Myriad Genetics worth $8K as of Q1 2019.
Alpha Quant Advisors left its Myriad Genetics share count unchanged in Q1 2019.
Myriad Genetics made up 0.01% of Alpha Quant Advisors's portfolio in Q1 2019, its #266 holding.
Alpha Quant Advisors first reported a position in Myriad Genetics in Q4 2018 and has held it in 2 quarters since.
262 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2019.

Based on Alpha Quant Advisors's 13F filing for Q1 2019, filed 8 May 2019.